Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008306871> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2008306871 endingPage "345" @default.
- W2008306871 startingPage "344" @default.
- W2008306871 abstract "The backbone of current cytotoxic treatment of metastatic colorectal cancer (mCRC) consists of a fluoropyrimidine together with either oxaliplatin (XELOX/FOLFOX) or irinotecan (XELIRI/FOLFIRI). With an overall objective response rate of approximately 50% for either treatment combination, a major unsolved problem is that no predictors of response to these treatments are available. To address this issue, we profiled 742 microRNAs in laser-capture microdissected cancer cells from responding and non-responding patients receiving XELOX/FOLFOX as first-line treatment for mCRC, and identified, among others, high expression of miR-625-3p, miR-181b and miR-27b to be associated with poor clinical response. In a validation cohort of 94 mCRC patients treated first-line with XELOX, high expression of miR-625-3p was confirmed to be associated with poor response (OR = 6.25, 95%CI [1.8; 21.0]). Independent analyses showed that miR-625-3p was not dysregulated between normal and cancer samples, nor was its expression associated with recurrence of stage II or III disease, indicating that miR-625-3p solely is a response marker. Finally, we also found that these miRNAs were up-regulated in oxaliplatin resistant HCT116/oxPt (miR-625-3p, miR-181b and miR-27b) and LoVo/oxPt (miR-181b) colon cancer cell lines as compared with their isogenic parental cells. Altogether, our results suggest an association between miR-625-3p and response to first-line oxaliplatin based chemotherapy of mCRC." @default.
- W2008306871 created "2016-06-24" @default.
- W2008306871 creator A5003454059 @default.
- W2008306871 creator A5020108110 @default.
- W2008306871 creator A5025120810 @default.
- W2008306871 creator A5027160662 @default.
- W2008306871 creator A5031681498 @default.
- W2008306871 creator A5056345420 @default.
- W2008306871 creator A5073405977 @default.
- W2008306871 creator A5075765455 @default.
- W2008306871 creator A5082612818 @default.
- W2008306871 creator A5090928234 @default.
- W2008306871 date "2009-09-01" @default.
- W2008306871 modified "2023-09-25" @default.
- W2008306871 title "6076 BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection" @default.
- W2008306871 doi "https://doi.org/10.1016/s1359-6349(09)71171-1" @default.
- W2008306871 hasPublicationYear "2009" @default.
- W2008306871 type Work @default.
- W2008306871 sameAs 2008306871 @default.
- W2008306871 citedByCount "16" @default.
- W2008306871 countsByYear W20083068712012 @default.
- W2008306871 countsByYear W20083068712014 @default.
- W2008306871 crossrefType "journal-article" @default.
- W2008306871 hasAuthorship W2008306871A5003454059 @default.
- W2008306871 hasAuthorship W2008306871A5020108110 @default.
- W2008306871 hasAuthorship W2008306871A5025120810 @default.
- W2008306871 hasAuthorship W2008306871A5027160662 @default.
- W2008306871 hasAuthorship W2008306871A5031681498 @default.
- W2008306871 hasAuthorship W2008306871A5056345420 @default.
- W2008306871 hasAuthorship W2008306871A5073405977 @default.
- W2008306871 hasAuthorship W2008306871A5075765455 @default.
- W2008306871 hasAuthorship W2008306871A5082612818 @default.
- W2008306871 hasAuthorship W2008306871A5090928234 @default.
- W2008306871 hasConcept C121608353 @default.
- W2008306871 hasConcept C126322002 @default.
- W2008306871 hasConcept C143998085 @default.
- W2008306871 hasConcept C2776694085 @default.
- W2008306871 hasConcept C2776705615 @default.
- W2008306871 hasConcept C2777802072 @default.
- W2008306871 hasConcept C2777909004 @default.
- W2008306871 hasConcept C2778260052 @default.
- W2008306871 hasConcept C2780259306 @default.
- W2008306871 hasConcept C2780962732 @default.
- W2008306871 hasConcept C526805850 @default.
- W2008306871 hasConcept C71924100 @default.
- W2008306871 hasConceptScore W2008306871C121608353 @default.
- W2008306871 hasConceptScore W2008306871C126322002 @default.
- W2008306871 hasConceptScore W2008306871C143998085 @default.
- W2008306871 hasConceptScore W2008306871C2776694085 @default.
- W2008306871 hasConceptScore W2008306871C2776705615 @default.
- W2008306871 hasConceptScore W2008306871C2777802072 @default.
- W2008306871 hasConceptScore W2008306871C2777909004 @default.
- W2008306871 hasConceptScore W2008306871C2778260052 @default.
- W2008306871 hasConceptScore W2008306871C2780259306 @default.
- W2008306871 hasConceptScore W2008306871C2780962732 @default.
- W2008306871 hasConceptScore W2008306871C526805850 @default.
- W2008306871 hasConceptScore W2008306871C71924100 @default.
- W2008306871 hasIssue "2" @default.
- W2008306871 hasLocation W20083068711 @default.
- W2008306871 hasOpenAccess W2008306871 @default.
- W2008306871 hasPrimaryLocation W20083068711 @default.
- W2008306871 hasRelatedWork W1952302484 @default.
- W2008306871 hasRelatedWork W1985338763 @default.
- W2008306871 hasRelatedWork W2060371502 @default.
- W2008306871 hasRelatedWork W2072155890 @default.
- W2008306871 hasRelatedWork W2083894790 @default.
- W2008306871 hasRelatedWork W2087290377 @default.
- W2008306871 hasRelatedWork W2134986421 @default.
- W2008306871 hasRelatedWork W2405565070 @default.
- W2008306871 hasRelatedWork W2416369235 @default.
- W2008306871 hasRelatedWork W2417717847 @default.
- W2008306871 hasVolume "7" @default.
- W2008306871 isParatext "false" @default.
- W2008306871 isRetracted "false" @default.
- W2008306871 magId "2008306871" @default.
- W2008306871 workType "article" @default.